Ardelyx Q2FY26 Results: Revenue hits record $118M, IBSRELA guide cut
- Ardelyx reported record Q2 2026 revenue of $118 million, up 31% YoY, with IBSRELA contributing $86.2 million and XPHOZAH $31.9 million.
- Full-year 2026 IBSRELA revenue guidance was lowered to $350-$370 million due to payer hurdles slowing new patient starts, while XPHOZAH guidance remained at $110-$120 million.
- Net loss narrowed to $16.7 million from $19.1 million in Q2 2025, supported by $281.8 million in cash and investments.
- Operating expenses rose significantly, with R&D at $26.1 million and SG&A at $101.4 million, reflecting investments in clinical trials and commercial access teams.
- The company withdrew its long-term $750 million revenue target for XPHOZAH but reaffirmed a path to sustained profitability in 2027.
*this image is generated using AI for illustrative purposes only.
Ardelyx (NASDAQ: ARDX) reported record second-quarter 2026 revenue of $118 million, a 31% year-over-year increase, driven by strong performance from its primary products, IBSRELA and XPHOZAH.
Despite the top-line growth, the company narrowed its net loss to $16.7 million from $19.1 million in the prior year period. However, facing significant payer hurdles that impacted new patient access for IBSRELA, Ardelyx lowered its full-year 2026 revenue guidance for the drug while maintaining its XPHOZAH outlook.
Financial Performance
Total product revenue reached $118 million in Q2 2026, compared to $90 million in Q2 2025. The company ended the quarter with $281.8 million in cash, cash equivalents, and short-term investments. During the quarter, Ardelyx drew down $50 million from its existing credit facility with FLR for general corporate purposes.
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Total Revenue | $118 million | $90 million | +31% |
| Net Loss | $16.7 million | $19.1 million | Narrowed |
| R&D Expenses | $26.1 million | $15.7 million | +66% |
| SG&A Expenses | $101.4 million | $84 million | +21% |
Revenue from IBSRELA grew 33% year-over-year to $86.2 million, while XPHOZAH revenue increased 27% to $31.9 million. Operating expenses rose significantly, with research and development costs jumping to $26.1 million from $15.7 million, primarily due to development activities and patient enrollment for the EXCEL Phase 3 clinical trial in chronic idiopathic constipation (CIC). Selling, general, and administrative expenses increased to $101.4 million from $84 million, reflecting deliberate investments to address access barriers for IBSRELA.
What the Numbers Show
The divergence between top-line growth and operating expense expansion highlights the company’s strategic pivot toward aggressive commercial support. While revenue grew 31%, SG&A expenses surged 21%, reaching $101.4 million—nearly equaling total quarterly revenue of $118 million. This indicates that the cost of navigating payer hurdles and expanding the field reimbursement team is currently consuming most of the incremental revenue generated by product sales. Consequently, despite higher sales, the net loss only narrowed modestly, underscoring the high cost structure associated with overcoming market access friction.
Guidance Revisions and Outlook
Ardelyx revised its full-year 2026 guidance for IBSRELA down to a range of $350 million to $370 million, citing current market dynamics and proactive initiatives to increase access. This represents annual growth of more than 30% at the midpoint. The company maintained its full-year 2026 revenue guidance for XPHOZAH at $110 million to $120 million.
Regarding longer-term targets, Ardelyx withdrew its previous $750 million revenue guidance for XPHOZAH, opting to revisit internal assumptions amid uncertainty surrounding the end of the Temporary Disability Access Program Agreement (TDAPA) period and new quality measures. For IBSRELA, the company reaffirmed its path to achieving $1 billion in revenue but noted it is evaluating the timing given the evolving market dynamics.
Operational Challenges and Strategy
CEO Mike Raab noted that while demand for IBSRELA remains strong, payers have implemented significant hurdles, including stringent prior authorizations and step edits, which slowed new patient starts. Chief Commercial Officer Eric Foster outlined four strategic actions to address these barriers:
- Leveraging a doubled field reimbursement team to navigate cumbersome paperwork.
- Driving more prescriptions through the IBSRELA Pharmacy Network (IPN) to improve fulfillment rates.
- Expanding the sales organization to 144 representatives to increase engagement with high-writing healthcare providers.
- Initiating new direct-to-consumer activities in the second half of the year.
For XPHOZAH, the company faces challenges following a June 26 decision by the D.C. Circuit Court of Appeals affirming the dismissal of its lawsuit against CMS, keeping oral-only phosphate-lowering drugs in the bundle. Ardelyx stated it will no longer pursue further litigation on this matter.
Path to Profitability
Chief Financial Officer Sue Hohenleitner projected that Ardelyx will achieve sustained profitability in 2027. The company plans to manage spending with discipline, revising its 2026 operating expense guidance to be below $500 million. Ardelyx emphasized that it is self-sustaining, funding its operations and pipeline from its revenue base while advancing its next-generation NHE3 inhibitor and tenapanor patent estate.
How effective will Ardelyx's expanded field reimbursement team and direct-to-consumer initiatives be in overcoming payer prior authorization hurdles for IBSRELA in the second half of 2026?
What specific impact will the expiration of the Temporary Disability Access Program Agreement (TDAPA) have on XPHOZAH's revenue trajectory and market share in 2027?
Given the significant increase in R&D expenses, what is the timeline and probability of success for the EXCEL Phase 3 trial for chronic idiopathic constipation, and how might it diversify Ardelyx's revenue stream?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
